OBJECTIVES
To describe how antibiotic absorption and elimination can vary depending on the route of administration, the age of the child and function of the organs involved in antibiotic metabolism. 2. To be able to discuss the fact that the antibiotic exposure to the pathogen, over time, varies from tissue to tissue but can be measured at many target sites where the infections actually occur, such as the bloodstream, cerebrospinal fluid or middle ear fluid. 3. To describe the variables providing data to the Monte Carlo simulation. 4. To recall that data used to describe the variables in a published Monte Carlo simulation in a journal may not necessarily reflect the data that would be used to describe those variables for a particular physician's own patient.
There is a pressing need for new antiinfective therapy in pediatrics with more active, better tolerated, safer and more easily administered agents. An ever increasing number of drug-resistant pathogens are responsible for community-acquired as well as nosocomial infections. Unfortunately drug development is a difficult, complicated, costly and risky process for those who seek to bring new therapies to children. Many bridges must be crossed before a new antiinfective is approved by the US Food and Drug Administration (FDA).
1 To enhance our ability to predict which dose of antibiotic effectively treats which organisms, mathematical models such as the Monte Carlo simulation incorporate many of the important variables that influence outcome. These mathematical constructs can be used to help us understand which factors are most important in treatment success and give us insight into why a certain dose of antibiotic might work against a pathogen in one situation but not another. They may also help us in designing clinical trials by minimizing the number of children studied while not compromising our analysis of drug efficacy.
In the sections that follow, we address antiinfective development in pediatrics, the factors involved in achieving microbiologic and clinical success in treating an infection and the mathematical synthesis that considers microbiologic, pharmacokinetic and pharmacodynamic variables and presents us with the probability that a certain dose of a specific antibiotic can cure a particular infection in a defined population of children.
use, the FDA may assist with a review of the proposed plans for drug development if the developer submits an investigational new drug application to the agency. Ongoing communication with the FDA during drug development allows for continuing assessment of drug safety and efficacy as new information becomes available. Initial animal toxicology tests are pursued before the compounds are ever considered for human use. If no significant toxicity is demonstrated with the antibiotic exposure required for clinical efficacy in animal models, the compound progresses into human Phase I trials in adults where the initial single dose pharmacokinetics and safety are assessed. If single dose studies are successful in adults, multiple dose studies are performed to increase the duration of drug exposure that would be used in a treatment course. Phase II studies in adults are designed to treat infections caused by the pathogens for which the antibiotic displays in vitro activity. Evaluation of drug exposure during a full treatment course allows for a better assessment of drug accumulation and safety. If the Phase II trials are successful, then Phase III trials begin: these are large scale, costly, labor-intensive clinical trials that randomize the patients requiring therapy between the new agent and the current standard of therapy (or placebo, if no alternative therapy exists). The number of patients required for the study, the number of positively identified pathogens and the clearly defined clinical and microbiologic outcomes are chosen to allow for a statistical analysis to demonstrate at least equivalence, if not superiority of the new agent to current therapy.
1, 2 The desired outcomes for antiinfective drug therapy have been defined by a collaboration between the FDA, infectious diseases physicians and the pharmaceutical industry. The final protocols are reviewed and approved by the FDA before starting the clinical trial to ensure that the study of efficacy and safety is clinically and statistically valid. Phase II and III trial design may now benefit from population-based computer modeling of pharmacokinetics, as well as pharmacodynamics, to allow for the most efficient clinical trial design to reach the required endpoints with the fewest patients enrolled. A prospective trial specifically designed with assessments of pharmacodynamic relationships was performed for levofloxacin by Preston et al. 3 After successful Phase III clinical trials in adults, the pharmaceutical sponsor usually applies to the FDA for approval to market the antibiotic for adults in the United States for the indications specifically studied in the Phase III protocol. This new drug application (NDA) is reviewed extensively by the FDA. Within 6 to 10 months of submission of the NDA, a public forum may be convened, if needed, at which time the FDA and the pharmaceutical sponsor review the microbiologic and clinical data collecting during drug development. Invited experts from many relevant disciplines, including clinical medicine, toxicology, epidemiology, pharmacology and statistics, are available to present in depth interpretations of the data regarding the proposed drug. With the information presented at the meeting, the FDA will approve the application as submitted, will approve the application with certain conditions attached, will request additional information or will reject the application with an explanation for the decision.
If the Phase III trials are successful in adults and a pediatric need exists, pediatric drug development usually begins, although concurrent development is also possible. The characteristics required of the compounds before investigation in children are listed on Table 1 . Phase I pediatric studies analyze single dose pharmacokinetic data in various ages of children for whom the drug will be used, from the neonate to the adolescent. As in adults, Phase II trials are generally "open label" (nonblinded) and noncomparative. After completion of the pediatric Phase III, randomized, comparative trials, the new drug application for certain pediatric indications is submitted to the FDA. A few months later, the drug may be approved for use in children for the specific indications studied if the drug appears to be safe and effective for those indications. The FDA can evaluate the safety and efficacy of the drug only for the indications submitted by the pharmaceutical sponsor; the FDA will usually not express an opinion, positive or negative, regarding indications for which data were not submitted. From the start of the search for a compound after identification of a clinical need, it may take up to 7 to 10 years to complete preclinical and clinical evaluations and have the agent approved by the FDA and be available to the clinician.
The use of antibiotics in children is clearly dictated by clinical need. A certain antibiotic may appear very helpful for treatment of a specific infection in children but may never have been studied by the pharmaceutical company or submitted to the FDA for that indication or particular age group. In these situations Phase IV studies in children investigate antibiotic therapy in types of infections not previously studied; investigate infections caused by new bacterial pathogens; investigate infections in target populations not initially stud- 
PROBABILITY OF CLINICAL CURE AND THE PRACTITIONER
In the practice of medicine, we rarely if ever achieve cure in 100% of our patients. In the treatment of infectious diseases, we may accept a risk of treatment failure in 10 to 20% of children for infections that are not life-threatening and have a low morbidity, such as cystitis. However, for other infections that are serious and routinely associated with significant morbidity and mortality, such as bacterial meningitis, we are unwilling to accept any treatment failure, assuming that our therapy produces fewer serious adverse outcome events than the infection itself. For some infections an extensive analysis of the cost effectiveness for evaluation and treatment of conditions to prevent morbidities within a certain level of risk may lay the foundation for a standard of care, as documented by the extensive literature regarding empiric therapy of occult bacteremia. 6 -8 In addition, for a specific infection in a specific child, some practitioners accept more or less risk of failure than others based on multiple nonmedical factors, including the physician's individual risk-taking behavior, an assessment of the reliability of the parents and the socioeconomic status and resources of the family. A standard of care is often a function of a consensus opinion from professional medical organizations, which may assign an appropriate and reasonable risk of failure for different infections. These decisions take into account the difficulties of clinical and laboratory diagnosis, the costs and side effects of treatment and the long term hazards of antibiotic resistance that accompany antibiotic use, weighed against decreasing the child's injury and suffering.
Monte Carlo simulation can determine the probability of a successful outcome in the treatment of an infection by using information regarding a specific dose of an antibiotic, to treat a specific bacterial pathogen at a specific tissue site. This probability of success can then be made known to the practitioner. If the practitioner wishes a higher probability of cure than that attainable at a certain antibiotic dosage, then higher doses (if tolerated and nontoxic) may be considered to achieve the preferred probability of cure. On the other hand, if the practitioner and the parent are willing to accept a lower probability of cure, then a lower dosage, often resulting in lower cost and fewer side effects, can be prescribed.
VARIABLES ASSESSED IN MONTE CARLO SIMULATION
For each factor evaluated in a Monte Carlo simulation, the inherent biologic variation can be defined; this variation results in a distribution of values. The factors evaluated include the concentrations of antibiotic found in serum or in infected tissues and the antibiotic susceptibility of pathogens. The distribution of values is then placed into a mathematical model of clinical and microbiologic efficacy to produce a "probability of target attainment" (also termed a probability of clinical cure) statistic.
Distribution of pathogen minimum inhibitory concentrations. For each species of pathogen, organisms display a range of susceptibilities to any given antibiotic. The range of MICs demonstrated for that organism by a specific antibiotic can be described ( Distribution of an antibiotic against three pathogens, demonstrating the variability of susceptibility that may be documented in collections of patient isolates. For each collection of organisms, variation in susceptibility to each antibiotic will exist. For some antibiotics the intrinsic variation will be minimal (Pathogen A), whereas for others it may be greater (Pathogen C). For yet other antibiotics, the distribution of MIC values will be broad and may represent one or more resistance determinants, as seen with the activity of penicillin G against Streptococcus pneumoniae (Pathogen B). range of MICs is great and involves multiple different resistance determinants, each potentially adding to the resistance detected in vitro (Antibiotic B). This variability may also differ by geographic region in the United States 9, 10 and the world 11 for the same organism. Furthermore the variability in susceptibility of pneumococci isolated from one tissue site may be different from that isolated from another; cultures of draining ears in children with otitis media yield organisms with greater antibiotic resistance than pneumococci isolated from blood or cerebrospinal fluid. 9 For methicillin-susceptible strains of Staphylococcus aureus, however, the range of susceptibilities to methicillin or nafcillin is intrinsically greater than that noted for penicillin against group A Streptococcus, although virtually all organisms fall within the "susceptible" range (Antibiotic C). The distribution of susceptibilities of Gram-negative enteric bacteria such as Escherichia coli to one drug such as ampicillin may be great, but the distribution of susceptibilities of the same organism to another drug, ceftriaxone, may be small. Published data exist for the range of susceptibilities of the most commonly used antibiotics for the most commonly isolated pathogens. Unfortunately the distribution of MIC values of organisms for a specific antibiotic changes with time and antibiotic pressure, and published data may not accurately reflect current susceptibility patterns for any particular location.
Antibiotic concentrations in serum. The distribution of serum antibiotic concentrations reflects the route of administration, with intravenous injection providing the most rapid and highest, most consistent concentrations compared with intramuscular or oral administration (Fig. 2) . More variability is present in the peak serum concentrations after intramuscular injection, with even more variability present if the antibiotic is given by mouth. Far greater variability exists under uncontrolled conditions of oral therapy in routine clinical practice than under the more rigorous conditions of oral therapy in a prospective, controlled investigation. Children who receive oral therapy eat a variety of foods that can affect absorption of the antibiotic; the antibiotic can be taken with or without food. Some children with concurrent gastroenteritis may have intestinal transit times much faster than in well children, preventing absorption of the antibiotic. Parents or physicians may "round-up" or "round-down" the dose administered to the child; suspensions of an antibiotic may or may not be shaken before administration, providing either too little or too much antibiotic compared with the recommended dosage. Thus in any population of children given the same antibiotic, a distribution of serum antibiotic concentrations is observed.
In addition an age-dependent change in elimination of antibiotics occurs. For the newborn, renal and hepatic maturation occur during the first weeks of life. Renal elimination of many drugs is significantly better in the first years of life than in school age children or adolescents. Because elimination of an antibiotic often depends on renal or hepatic function, renal or hepatic failure may increase the serum half-life of the antibiotic. All of these differences in antibiotic elimination based on antibiotic chemistry and the host absorption and elimination characteristics can lead to different serum concentrations after administration of a specified dose and consequently lead to different antibiotic exposures to the pathogen. The total antibiotic exposure can be expressed as the area under the serum concentration vs. time curve (AUC) and can be measured after administration of the antibiotic (Fig. 2) .
Distribution of antibiotic concentrations at the site of infection. Perhaps the best example of the need to measure antibiotic concentrations at a specific site is in the treatment of bacterial meningitis. The blood-brain barrier in normal children prevents passive diffusion of beta-lactam antibiotics (e.g. ampicillin) into cerebrospinal fluid (CSF). For an antibiotic to be effective, the antibiotic must achieve certain concentrations within the CSF; we need to know how much antibiotic gets into the CSF, how long it stays there and how much variation exists between children. In addition the degree of diffusion of antibiotics into the CSF may vary during the course of therapy based on the amount of meningeal inflammation present during the illness. Although the most accurate way to describe the FIG. 2. Effects of dose (mg/kg), dosing interval and route of administration on total drug exposure, as defined by the AUC and its relationship to the MIC of the pathogen being treated. Antibiotics administered intravenously with a long serum half-life of 6 h (Antibiotic A) achieve a relatively large AUC compared with antibiotics with a shorter half-life of 1 h (Antibiotic B), which require more frequent dosing (every 6 h in this example) to achieve similar drug exposure to the pathogen. Orally administered antibiotics (Antibiotic C) generally produce a much lower AUC than those administered iv. The MICs for penicillinsusceptible and -resistant S. pneumoniae are superimposed on the graph.
CSF concentrations in children is to measure multiple spinal fluid antibiotic concentrations in each child during every day of therapy, the ethical difficulties present in this type of sampling are obvious. In the end we usually collect both data from experimental animals, as well as limited data on CSF penetration from children in Phase I, II and III trials from which we attempt to correlate the CSF concentrations with serum concentrations. We can statistically develop a "distribution" of CSF values, based on the variation observed from children during the clinical trials. Subsequently we use the serum concentrations to predict the concentrations we are likely to achieve in the CSF.
In other tissue compartments such as the middle ear, the concentrations of antibiotic in fluid are intrinsically quite variable in children given the same dose of antibiotic, whether given orally 12 or parenterally 13 ( Figs. 3 and 4) . To quantify antibiotic exposure to middle ear pathogens, we need to measure the amount of antibiotic that enters the middle ear fluid in addition to measuring how long the antibiotic remains in this fluid at the site of infection to arrive at an accurate assessment of antibiotic exposure to the bacterial pathogens. Although we can easily define the concentration-time profile of an antibiotic in serum, it is more difficult to define the elimination half-life from other sites, such as middle ear fluid or CSF. Data collected on a prolonged half-life of ceftriaxone in middle ear fluid 13, 14 of ϳ24 h (compared with the serum half-life of 4 to 6 h), supported the application for FDA approval for a single dose in the treatment of uncomplicated otitis media. 4 In this instance the "time above MIC during the 24-h dosing interval" (TϾMIC) for middle ear fluid after a single dose is much greater than the TϾMIC in serum. Because the penetration of an antibiotic into an infection site is most often described by a first order kinetic process with delivery from the serum compartment, we can usually predict accurately the antibiotic concentrations achieved at most infection sites by the serum AUC profile.
Pharmacodynamics. The pharmacodynamic aspect of clinical and microbiologic outcomes is derived from both the in vitro characteristics of bacterial killing over time and by observations of success and failure after the actual clinical use of an antibiotic over a range of doses. An analysis of which patients are treatment successes and treatment failures at different doses and schedules of antibiotic (which correlate with differences in drug exposure to the pathogen) may give one insight into whether one pharmacodynamic factor may be better associated with cure than another. Although a larger dose gives a greater C max , a larger AUC, as well as a longer time above the MIC, a statistical "best fit" may link clinical and microbiologic cure by a specific antibiotic against a specific pathogen more closely with one or another of these outcome-linked variables: the AUC:MIC; the C max :MIC; or TϾMIC. 3, 15, 16 The correlation of drug exposure with a successful microbiologic outcome varies with the type of antibiotic and the particular pathogen. For some antibiotics the degree of killing of the pathogen is directly proportional to the concentration of antibiotic (concentrationdependent killing) as noted for gentamicin in Figure  5A . However, when the organism is exposed to ampicillin, killing is not enhanced once the concentration of antibiotic is 2 to 4 times greater than the MIC (Fig. 5B) . Antibiotics that kill a pathogen in a concentrationdependent manner may demonstrate the best pharmacodynamic correlates of cure by either the ratio of the maximum (peak) serum concentration of antibiotic to the MIC of the organism (C max :MIC, or peak:MIC) or by the AUC:MIC ratio. Other antibiotics that do not kill the pathogen any more quickly with higher concentrations may just need to be exposed to the organism for a certain time period to achieve the same result. 15 For these antibiotics the TϾMIC may be the best predictor of clinical success. Antibiotics that generally demonstrate concentration-dependent killing include the aminoglycosides and fluoroquinolones, whereas those most often demonstrating time-dependent killing are the beta-lactam antibiotics (penicillins, cephalosporins and carbapenems).
For some beta-lactam antibiotics with a short serum half-life, multiple small doses each day or continuous infusions of the antibiotic will often provide a longer TϾMIC and a better cure rate than if only a few large doses of the same antibiotic are given during the day (Fig. 2, Antibiotic B) .
We can also determine a particular value of the outcome-linked variable (AUC:MIC, C max :MIC, or TϾMIC) above which we are statistically likely to achieve a cure. This critical value is our target, taking into account both antibiotic exposure and the susceptibility of the pathogen. In a retrospective evaluation Forrest et al. 17 noted a much greater microbiologic and clinical cure rate for Gram-negative infections when the AUC:MIC ratio was Ͼ125, yielding ϳ80% success compared with only 30 to 40% success when the AUC: MIC ratio was Ͻ125. Indeed it seems reasonable that both a larger dose (producing a greater AUC) and a more susceptible organism (a lower MIC) would favor success during therapy.
To use otitis media as an example, published articles exist for several antibiotics on clinical and microbiologic efficacy in otitis. The published data define the number of children who were treated with a specific antibiotic for a specific pathogen, such as S. pneumoniae or Haemophilus influenzae. We know the dosage of antibiotic used in the study, so we can predict the serum concentrations and the middle ear fluid concentrations achieved in the "average" child in the study. We also know how many children actually failed therapy for each specific pathogen. Craig and Andes 18 retrospectively analyzed several studies, plotting the success of therapy with each antibiotic studied against the percentage of time over a 24-h dosing interval when the serum concentration of antibiotic was greater than the MIC (TϾMIC) (Fig. 6) . As the amount of time above the MIC increased, so did the likelihood of success. Those children with the lowest serum concentrations during the 24-h dosing interval (which would correlate with low middle ear fluid concentrations) had the lowest rates of clinical success, whereas those with the highest antibiotic concentrations had the highest rates of cure. They found in general that the cure rates with beta-lactams, macrolides and trimethoprim-sulfamethoxazole were reasonable in the treatment of otitis even if the proportion of time above the MIC was only 40% of the 24-h dosing interval. Achieving even greater time above the MIC during a 24-h interval did not appear to produce significantly improved cure rates. The magnitude of this effect in which the antibiotic need not always be present at the site of infection at concentrations above the MIC to produce a cure varies with the pathogen, the tissue site of infection and the type of antibiotic. For certain organisms poor growth is noted in vitro for several hours after exposure to a certain class of antibiotic, even when no antibiotic remains in contact with the organism (persistent, or postantibiotic effect). 19 An additional observation from clinical studies suggests that the target antibiotic exposure for a successful outcome may be different for Gram-negative pathogens and Gram-positive pathogens, even when patients are treated with the same antibiotic. An example is seen with fluoroquinolones, where a target AUC:MIC ratio of 80 to 100 is needed for Gram-negative organisms, whereas for Gram-positive pathogens such as S. pneumoniae, one needs only an AUC:MIC ratio of ϳ30. In extrapolating all of these observations to the design of clinical trials with new agents, aiming for a certain target exposure of antibiotic may well allow the use of a dose of antibiotic that maximizes outcome while lowering the antibiotic exposure, toxicity and cost of therapy. 20 Pharmacodynamics may also help address the issue of the development of antibiotic resistance, as recently reviewed by Drusano. 21 Achieving the target value for the relevant pharmacodynamically linked covariate in treated children predicts the microbiologic eradication of the majority of a population of infecting pathogens. However, in every population of organisms, resistant strains may be present at a certain frequency, based on many possible mechanisms of resistance. Some resistance mechanisms manifest in MICs that are 2-to 4-fold greater than the wild-type organisms (e.g. organisms with efflux pumps, or deficiencies in outer membrane porins). If the drug exposure, or dose of antibiotic administered, can be tailored to achieve the target pharmacodynamically linked variable for the more resistant organisms with the higher MICs, microbiologic failures in patients are less likely to occur. This strategy has significant implications in the treatment of nosocomial infections, because we may be able to decrease the development of resistant organisms as well as to achieve a greater rate of microbiologic cure.
MONTE CARLO SIMULATION
All of the above factors that determine whether a certain dose of antibiotic is effective against a particular pathogen can now be brought together in mathematical models to predict clinical outcomes in an individual or in a population of patients. 3, 15, 16, 20, 22, 23 Each factor can be described by a distribution of values. The pathogen involved has a probability of being inhibited at a certain MIC (Fig. 7) . That is, we can obtain a large collection of a particular pathogen and determine the fraction (proportion) of the population that is inhibited at each specific MIC. Likewise, we can describe a distribution of AUC values within a population, based on variations of absorption and elimination of that antibiotic after administration. Each individual within the population studied has a probability that he/she will achieve a certain AUC. Knowing these probabilities from actually measuring values in a limited number of patients, we can mathematically create an AUC distribution for 10 000 subjects (Fig. 8) .
Ambrose et al. 23 studied actual pneumococcal infections in adults treated with either levofloxacin or gatifloxacin. By analyzing microbiologic cures and fail- ures in these patients as a function of the AUC:MIC ratio achieved and using each patient's individually measured AUC and the MIC of the isolated organism, they were able to ascertain the minimal AUC:MIC ratio associated with a very high probability of clinical cure, which appears to be ϳ30 (Fig. 9) . Indeed data analyses of this kind are used to derive the target exposure AUC:MIC ratio that is associated with cure for those organisms and antibiotics for which the AUC: MIC ratio is the best pharmacodynamic outcome variable. Similar analyses can be performed for organisms and antibiotics for which TϾMIC is the best outcome variable (Fig. 6) .
We now can ask some simple questions of our database. If we know the therapeutic target that we wish to attain (e.g. AUC:MIC ratio of 30 for levofloxacin against S. pneumoniae) and we assume that the MIC of the patient's pneumococcal isolate is 0.25 g/ml, we can ask, "What fraction of 10 000 simulated subjects (Fig.  8) can attain the target?" The answer is plotted (Fig.  10 ), and the question is then reasked for increasing MICs of 0.5 g/ml, then 1.0 g/ml and so on until the fraction of the patients attaining the goal is zero or some very low fraction. 24 Before knowing the MIC of any particular isolate, we can easily calculate the probability of attaining the target AUC:MIC ratio for the whole population of patients infected by organisms with a defined distribution of MICs. This is done by multiplying the probability of target attainment at a specific MIC by the fraction of all organisms in the defined collection with that MIC, knowing that these fractions add up to 1. By adding each probability calculated at each MIC, we arrive at the overall probability of achieving our target AUC:MIC, accounting for all the variability in drug pharmacokinetics between patients and all the variability in MIC values for the pathogen of interest.
As one might expect, Monte Carlo simulation would suggest that a different dose might be needed for each pathogen, as the MIC distribution for each pathogen under consideration may be different. Because the tissue concentrations of antibiotic might be different for each infection site, one can now predict that different therapeutic dosages of a single antibiotic might be necessary for each infection under consideration, with central nervous system infections like meningitis requiring some of the highest mg/kg doses in order to achieve cure. 25, 26 This has in fact been the standard of practice for many years. On the other hand high cure FIG. 8 . Distribution of subjects achieving a particular AUC value in a simulated population of 10 000 adults given a 500-mg dose of levofloxacin, recognizing that biologic variation exists in this population with respect to drug absorption, distribution and elimination.
FIG. 9. Relationship between free drug AUC:MIC ratio for two fluoroquinolones and the probability of clinical cure. The breakpoint value of 30 was derived from these data. OO, model-based probability of cure. Adapted from Reference 23, with permission. FIG. 10 . The target attainment rate with a dosing regimen in adults of 500 mg of levofloxacin once daily, as a function of the MIC of S. pneumoniae. Monte Carlo simulation of 10 000 subjects was based on target attainment values from an analysis of 272 patients with serious community-acquired infections 24 and suggest a very high probability of cure (target attainment rates of 100%) for organisms demonstrating an MIC of 0.5 g/ml or less. With higher MICs the target attainment rate decreases, with a very low likelihood of cure (target attainment rate of 0%) for organisms demonstrating an MIC of 4.0 g/ml or greater.
rates of bloodstream infections are achieved at a lower dosage of antibiotic than with central nervous system infections, as we have much higher drug exposure profiles in the blood; children with urinary tract infections require a lower dosage of an antibiotic that is concentrated in and excreted by the kidneys than if treated with an antibiotic that is concentrated in and cleared by the liver. If we look at populations that eliminate drugs poorly (producing much higher drug exposures than normal populations), Monte Carlo simulation suggests lower dosages than for healthy, normal populations. For children in renal failure being treated with antibiotics characterized by renal elimination, a lower dosage than used in healthy children is likely to attain the target exposure associated with cure.
One could also arrive at different dosages of an antibiotic based on the seriousness of an infection and the need to achieve a higher probability of cure in children who might suffer greater morbidity or even mortality if not treated properly. One may accept a cure rate of Ͻ90% for a population of children with bacterial cystitis but require a cure rate approaching 100% for severe bacterial pneumonia. This should produce a recommendation for different dosages of antibiotic for different types of infections, with lifethreatening infections requiring the highest dosages.
Monte Carlo simulation can also calculate appropriate dosages of antibiotics for immunocompromised populations. Understanding that most antibiotics are tested in normal, immunocompetent hosts before FDA approval, these dosing recommendations apply only to normal hosts. The cure for most bacterial infections depends on the host immune system, particularly polymorphonuclear leukocytes, to help eradicate the pathogens. When the host response is absent or severely compromised, as in a child with neutropenia, it would be expected that the overall dosage of antibiotic required to achieve a cure would be greater. In other words the target attainment value required for cure would be higher in this population than in normal, healthy children. To define the value necessary for cure, one would have to collect data on microbiologic success and failure at different antibiotic exposures (AUC:MIC ratio or TϾMIC, depending on the antibiotic and the organism) from experimental animals with neutropenia, [27] [28] [29] adults with neutropenia or clinical trials in children with neutropenia. Once the clinical trials define the value necessary for clinical and microbiologic success, Monte Carlo simulation can predict the probability of cure at any particular dosage of antibiotic for the pathogen in question. In this population we would ask a Monte Carlo simulation to define the dosage necessary to achieve cure in close to 100% of the infections caused by Pseudomonas aeruginosa. With this example opportunities for the further refinement of Monte Carlo simulation begin to appear. A certain clinical study in children with fever and neutropenia may have been performed at an institution in which all of the P. aeruginosa isolates were very susceptible to a particular antibiotic, e.g. ceftazidime.
However, a few years later, in your own institution, the resistance of P. aeruginosa to ceftazidime is twice that of organisms isolated in the earlier study. By placing your institution's Pseudomonas MIC distribution into your analysis, you are able to determine what dose of ceftazidime is needed for your own population of patients to achieve the desired target TϾMIC (the pharmacodynamically linked covariate that best describes the effects of ceftazidime against P. aeruginosa). You may discover at a certain level of resistance to ceftazidime that even with the highest tolerated dosage of this drug you will only produce a cure in 60% of your patients. With this knowledge you can logically and effectively use alternative agents that remain active against P. aeruginosa in your hospital. In this way the recognized differences in susceptibility in organisms among countries, regions, cities, hospitals and wards within a hospital can be taken into account. We need only enter the accurate microbiologic data into the simulation to obtain relevant advice for our patients.
For infections involving multiple pathogens, such as complicated appendicitis, a single broad spectrum drug may be assigned a probability of cure for each organism present; alternatively multiple narrow spectrum agents can each be assigned a probability of success in treating their targeted pathogens. It should be possible to select the dosage(s) that will achieve 95% overall success based on the MICs of the pathogens, the exposure of the pathogens to antibiotics in the abdomen after surgical drainage and the mathematical constructs that best predict a favorable outcome.
HOW THE CLINICAL LABORATORY DEFINES "SUSCEPTIBLE" AND "RESISTANT"
Just as we can select an antibiotic dosage that achieves a high probability of attaining the required target exposure for organisms with relatively low MICs, we begin to understand that for organisms with higher MICs we are unlikely to achieve the required target exposure, as seen in Figure 10 . According to this example pneumococci with MICs of 2 or greater are likely to fail treatment in Ͼ80% of treatment courses. In this way we can establish the MIC value for patient isolates that should be reported as "susceptible" or "resistant."
A distribution of antibiotic exposures in a population of patients can be assessed for acceptable safety and tolerability. The pharmacodynamic variable for the particular antibiotic and pathogen (AUC:MIC ratio, or TϾMIC) can be entered into the simulation for all of the possible MIC values to determine the proportion of patients at each MIC that would achieve target exposures (e.g. an AUC:MIC of 30 or greater or a TϾMIC of 40% or greater). With this approach the organism MICs that would allow a high proportion of patients (90% or greater) to attain the target exposure would be defined as "susceptible," whereas organisms demonstrating MICs that did not achieve this target exposure would be labeled as nonsusceptible or resistant. Based on the data presented in Figure 10 , organisms with an MIC of 0.5 g/ml or less are associated with extremely high rates of target attainment and would be considered susceptible. Thus the information on antibiotic susceptibility for a patient isolate from the clinical laboratory has considered the variations in antibiotic exposure to the patients and provides greater insight into expectations for clinical success.
The use of pharmacodynamic concepts and Monte Carlo simulation are now integral to establishing susceptibility criteria by the National Committee for Clinical Laboratory Standards and other consensus and regulatory authorities. Such an analysis was recently a key consideration in the revision of the susceptibility "breakpoints" for ceftriaxone and cefotaxime against S. pneumoniae for nonmeningitis isolates. 30 The apparent greater activity of these antibiotics against S. pneumoniae provided clarification for the usefulness of these agents in the treatment of penicillin-nonsusceptible pneumococci.
CONCLUSIONS
The clear advantage of Monte Carlo simulation, assuming that the appropriate data have been collected, is that one has the ability to predict for any pathogen, for any infection and for any patient population the likelihood of treatment success with a specific dosage of an antibiotic. The capability will exist in the future to identify an infection in a child, enter the relevant data into a hand-held computing device and have Monte Carlo simulation give you suggestions on the dosages of antibiotics you can use and the probability of treatment success of each dosage. The disadvantage of this or any other computer program, is that the conclusions are only as valid as the data entered into the program. If any of the variables are inaccurate, from the pathogens and their MICs, to the drug handling and pharmacodynamics in a specific patient population, Monte Carlo simulation will also be inaccurate. At present we must rely on probabilities calculated from large studies of specific infections in well-defined, reasonably healthy populations. Studies evaluating outcomes with less common pathogens or with unusual patient populations may not be available. It is unlikely that we will have completely accurate data for the necessary calculations in any given child, highlighting the continuing need for clinical interpretation of the Monte Carlo simulation-generated probabilities. Knowledge of the factors that are fundamental to the calculation of probabilities in Monte Carlo simulation allows one both to anticipate when the failures may occur and to offer new recommendations for successful therapy.
